U.S. cases of vaping-related illness rise to 530 as outbreak widens

Send a link to a friend  Share

[September 20, 2019]  By Julie Steenhuysen

CHICAGO (Reuters) - U.S. health officials said on Thursday there are now 530 confirmed and probable cases and seven deaths from severe lung-related illnesses tied to vaping, and there are no signs that the outbreak is easing.

That is up from 380 cases reported a week ago as health officials link more illnesses and deaths to vaping. Three-fourths of the cases are male, and two-thirds are between the ages of 18 and 34.

The U.S. Food and Drug Administration is now investigating more than 150 products and substances and said it has activated its criminal investigations arm to explore the supply chain of vaping products and identify the cause of the outbreak. No individual vapers will be targeted, said Mitch Zeller, director of the FDA's Center for Tobacco Products.

Zeller said no single substance or compound, including tetrahydrocannabinol (THC), the high-inducing component of marijuana, or Vitamin E acetate, has been linked to all of the cases so far.

The Centers for Disease Control and Prevention (CDC) has confirmed seven people have died from vaping-related illness. The confirmed deaths were reported in California (2), Illinois, Indiana, Kansas, Minnesota and Oregon.

[to top of second column]

"We do expect others," Dr. Anne Schuchat, principal deputy director of the CDC, told reporters, referring to the number of deaths.

A Missouri man in his 40s died of a lung illness associated with the use of e-cigarettes earlier this week, the eighth vaping death in the United States and the first death in Missouri, state health officials announced on Thursday afternoon.

(Reporting by Julie Steenhuysen and Brendan O'Brien in Chicago and Gabriella Borter in New York; Editing by Sonya Hepinstall and Matthew Lewis)

[© 2019 Thomson Reuters. All rights reserved.]

Copyright 2019 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

 

Back to top